Short and long term anti-inflammatory effects of bosentan therapy in patients with pulmonary arterial hypertension: relation to clinical and hemodynamic responses

Author： Karavolias George K   Georgiadou Panagiota   Gkouziouta Angeliki   Kariofillis Panagiotis   Karabela Georgia   Tsiapras Dimitrios   Sbarouni Eftihia   Chaidaroglou Antigoni   Degiannis Dimitrios   Adamopoulos Stamatis   Voudris Vassilis  

Publisher： Informa Healthcare

ISSN： 1472-8222

Source： Expert Opinion on Therapeutic Targets, Vol.14, Iss.12, 2010-12, pp. : 1283-1289

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Long-term benefits of bosentan in pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1404, 2003-01 ,pp. : 13-13

Adis International

Access to resources Recommend Favorite

Bosentan: In Pediatric Patients with Pulmonary Arterial Hypertension

By Carter Natalie J.   Keating Gillian M.  

Pediatric Drugs, Vol. 12, Iss. 1, 2010-02 ,pp. : 63-73

Adis International

Access to resources Recommend Favorite

Inhaled treprostinil is an effective, well-tolerated add-on therapy for patients with pulmonary arterial hypertension (PAH) treated with bosentan

By  

Inpharma, Vol. 1, Iss. 1561, 2006-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Treatment of pulmonary arterial hypertension with bosentan: from pathophysiology to clinical evidence

By Provencher Steeve   Sitbon Olivier   Simonneau Gérald  

Expert Opinion on Pharmacotherapy, Vol. 6, Iss. 8, 2005-07 ,pp. : 1337-1348

Informa Healthcare

Access to resources Recommend Favorite

The long-term use of imatinib may be beneficial for patients with pulmonary arterial hypertension

By  

Inpharma, Vol. 1, Iss. 1555, 2006-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite